Overview

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

Status:
Terminated
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The aim of this phase I/II trial is to determine the dose of daunorubicine to be associated with cytarabine and Imatinib for induction therapy in patients with chronic myelogenous leukemia in myeloid acute phase.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Poitiers University Hospital
Collaborators:
Ministry of Health, France
Novartis
Treatments:
Cytarabine
Daunorubicin
Imatinib Mesylate